SCHEMBL131795

SCHEMBL131795

CN(CCN(C)c1ccc([N+](=O)[O-])c2nonc12)C(=O)CI

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GSTM2 P28161 14/20 0.44
GSTP1 P09211 13/20 0.44
CNR2 P34972 1/20 0.40
SLC5A2 P31639 1/20 0.40
KCNH2 Q12809 1/20 0.39
NSD2 O96028 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23612900 0.88 MEN1 (0.52) MEN1KMT2AGSTM2GSTP1SLC5A2
SCHEMBL14140891 0.88 MEN1 (0.54) MEN1KMT2AGSTM2GSTP1SLC5A2
SCHEMBL6951880 0.86 MEN1 (0.52) MEN1KMT2AGSTM2GSTP1SLC5A2
SCHEMBL4295407 0.84 MEN1 (0.38) MEN1KMT2AGSTM2GSTP1CNR2
SCHEMBL26025 0.83 MEN1 (0.49) MEN1KMT2AGSTM2GSTP1CNR2
SCHEMBL3063567 0.81 MEN1 (0.52) MEN1KMT2AGSTM2GSTP1KCNH2
SCHEMBL6123423 0.81 MEN1 (0.51) MEN1KMT2AGSTM2GSTP1CNR2
SCHEMBL26054240 0.80 MEN1 (0.56) MEN1KMT2AGSTM2GSTP1
SCHEMBL18007677 0.79 KMT2A (0.61) MEN1KMT2AGSTM2GSTP1CNR2
SCHEMBL17914175 0.79 MEN1 (0.63) MEN1KMT2AGSTM2GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346641-A1 COMPOSITIONS AND METHODS FOR THIN FILAMENT MODULATION UNIV ARIZONA (US) 2025-11-13 US claimed
US-20240168032-A1 GLUCOSE BIOSENSORS AND USES THEREOF UNIV DUKE (US) 2024-05-23 US claimed
EP-3377898-B1 THERMOSTABLE GLUCOSE BIOSENSORS AND USES THEREOF UNIV DUKE (US) 2024-05-01 EP claimed
EP-3377904-B1 UREA BIOSENSORS AND USES THEREOF UNIV DUKE (US) 2024-05-01 EP claimed
EP-3377897-B1 LACTATE BIOSENSORS AND USES THEREOF UNIV DUKE (US) 2024-05-01 EP claimed
EP-4247968-A1 USE OF DEXTRAMER IN SINGLE CELL ANALYSIS Becton, Dickinson and Company (US) 2023-09-27 EP claimed
US-20220244266-A1 GLUCOSE BIOSENSORS AND USES THEREOF UNIV DUKE (US) 2022-08-04 US claimed
WO-2022109339-A1 USE OF DEXTRAMER IN SINGLE CELL ANALYSIS BECTON, DICKINSON AND COMPANY (US) 2022-05-27 WO claimed
US-20220064226-A1 Panel comprising Borrelia MHC multimers IMMUDEX APS (DK) 2022-03-03 US claimed
EP-3898666-A2 PANEL COMPRISING BORRELIA MHC MULTIMERS Immudex ApS (DK) 2021-10-27 EP claimed
WO-2010037395-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO claimed
EP-2155782-A2 MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES Dako Denmark A/S (DK) 2010-02-24 EP claimed
WO-2009106073-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE DAKO DENMARK A/S (DK) 2009-09-03 WO claimed
WO-2009039854-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS DAKO DENMARK A/S (DK) 2009-04-02 WO claimed
US-20090054532-A1 Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation SIRION THERAPEUTICS, INC. (US) 2009-02-26 US claimed
WO-2008116468-A2 MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES DAKO DENMARK A/S (DK) 2008-10-02 WO claimed
US-20060094063-A1 Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation SYTERA, INC. (US) 2006-05-04 US claimed
EP-1335984-A1 DETERMINATION OF HYDROPHOBIC COENZYME A ESTERS AND OTHER LIPIDS USING A BIOSENSOR COMPRISING A MODIFIED COENZYME A- AND ACYL-COA BINDING PROTEIN (ACBP) Biosensor APS (DK) 2003-08-20 EP claimed
US-20020142347-A1 Biosensor BIOSENSOR APS (DK) 2002-10-03 US claimed
WO-2002061096-A1 DETERMINATION OF HYDROPHOBIC COENZYME A ESTERS AND OTHER LIPIDS USING A BIOSENS OR COMPRISING A MODIFIED COENZYME A- AND ACYL- BINDING PROTEIN (ACBP) BIOSENSOR APS (DK) 2002-08-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054532-A1 Modulators of Retinol-Retinol Binding Protein (RBP)-Transthyretin (TTR) Complex Formation RBP1, TTR, RBP4 MEN1 4500/4885KMT2A 4838/4885GSTM2 3042/4885
US-20240168032-A1 GLUCOSE BIOSENSORS AND USES THEREOF GCK, GCKR, SLC2A4 MEN1 2391/4885KMT2A 4044/4885GSTM2 1036/4885
US-20220244266-A1 GLUCOSE BIOSENSORS AND USES THEREOF GCK, GCKR, SLC2A4 MEN1 2391/4885KMT2A 4044/4885GSTM2 1036/4885
US-20060094063-A1 Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation RBP1, TTR, RBP4 MEN1 4500/4885KMT2A 4838/4885GSTM2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.